Lumenis Presents Groundbreaking Findings in Laser Medicine at Annual ASLMS Conference

Lumenis Unveils Cutting-Edge Clinical Data in Savannah

Lumenis Be Ltd., a prominent player in the field of energy-based medical devices, has made significant strides in advancing aesthetic treatments, particularly in addressing skin and hair loss. This was underscored at the 45th Annual American Society for Laser Medicine and Surgery (ASLMS) Conference, held recently in Savannah, Georgia. The company is celebrating its 60th anniversary, and the presentations at the conference are a testament to its ongoing commitment to innovation and excellence in patient care.

Groundbreaking Research on FoLix

Of particular note during the conference was the introduction of FoLix, the first FDA-cleared non-ablative fractional laser designed specifically for hair loss treatment. Two pivotal studies presented set new benchmarks in the clinical validation of FoLix. The first, led by Dr. Jennifer Krejci from the Limmer Hair Transplant Center in Texas, involved the largest randomized prospective study conducted to date on the topic. The results show substantial improvements, with an impressive 82% of participants experiencing measurable benefits in terms of terminal hair count and overall follicular density.

Complementing these findings, Dr. Neil Sadick from Sadick Dermatology in New York discussed the mechanisms behind FoLix, revealing its ability to stimulate angiogenesis and promote dermal remodeling. These biological processes are crucial for effective hair loss treatment and signify a step forward in using laser technology for this purpose.

Innovations with ULTRApulse CO2 Laser

The ULTRApulse Alpha, another star of the conference, showcased its efficacy in treating rhinophyma—a condition characterized by the enlargement of sebaceous glands on the nose. The study highlighted a clinical trial involving 15 patients, revealing a high level of satisfaction and notable clinical improvements without complications. The combination of different laser applications was particularly effective, with every participant expressing willingness to recommend the treatment.

Advancements in Stellar M22™ XPL Technology

Lumenis also presented new data on the Stellar M22 platform, emphasizing advancements in Pulsed Light technology beneficial for treating larger areas of skin impacted by photodamage. This research indicated that a new method, integrating high-frequency glide techniques, significantly enhances treatment efficiency while minimizing discomfort. The outcome showed substantial improvements in skin quality without adverse effects, further validating stellar performance across various skin types and conditions.

Expert Insights from Lumenis Leadership

Tzipi Ozer-Armon, the company's CEO, emphasized the pivotal role of clinical evidence in driving innovation at Lumenis. She reinforced the mission of the company: to continually elevate the standards of patient care through cutting-edge laser solutions and to empower clinicians with advanced tools for superior outcomes. As patient expectations evolve, Lumenis remains at the forefront of addressing these changes with scientifically validated procedures.

Conclusion: A Bright Future for Aesthetic Medicine

With presentations revealing the impressive capabilities of devices like FoLix, ULTRApulse Alpha, and Stellar M22, Lumenis is indeed redefining the landscape of aesthetic medicine. Their ongoing dedication to harnessing advanced technologies in meeting patient needs signals a promising future for clinicians and patients alike, aiming for more effective and satisfying treatment outcomes in the years to come.

This year's ASLMS Conference proved to be an essential platform not just for showcasing groundbreaking innovations but also for fostering the exchange of ideas aimed at advancing the entire field of laser medicine. With a commitment to rigorous scientific research and a focus on clinical efficacy, Lumenis is poised to remain a leader in the medical aesthetics market for years to come.